Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Whan In Pharmaceutical Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Both of these 2 pending office actions are located within 1 distinct art unit, which provides a consistent administrative and technical framework for the portfolio. This concentration in 1 distinct art unit simplifies the procedural landscape while still requiring attention to examiner-specific nuances.
The company is working with 2 distinct examiners, with KIFLE, BRUCK being the busiest, currently managing 1 pending office action. With 2 distinct examiners each handling one of the 2 pending office actions, the company must manage two different individual perspectives within the same art unit. This structure allows for a focused technical strategy within the Biotechnology & Pharmaceuticals field while requiring the company to address the specific feedback of 2 distinct examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| NGUYEN, NGOC-ANH THI | 1 | 28.1% | +49.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719795 | MACROCYCLIC PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE CONTAINING SAME AS ACTIVE INGREDIENT | KIFLE, BRUCK | — |
| 18681299 | SUSTAINED-RELEASE MICROSPHERES COMPRISING DONEPEZIL | NGUYEN, NGOC-ANH THI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719795 | MACROCYCLIC PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE CONTAINING SAME AS ACTIVE INGREDIENT | KIFLE, BRUCK | — |
| 18681299 | SUSTAINED-RELEASE MICROSPHERES COMPRISING DONEPEZIL | NGUYEN, NGOC-ANH THI | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18719795 | MACROCYCLIC PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE CONTAINING SAME AS ACTIVE INGREDIENT | KIFLE, BRUCK | — | §102§103§112 | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18681299 | SUSTAINED-RELEASE MICROSPHERES COMPRISING DONEPEZIL | NGUYEN, NGOC-ANH THI | 1615 | §102§103§112 | Non-Final OA | — | Pending | Feb 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial